Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma

Autor: Oelmann, E. (Elisabeth), Stein, H. (Harald), Berdel, W.E. (Wolfgang), Herbst, H. (Hermann)

Publikováno v: PLoS ONE
PLoS ONE, Vol 10, Iss 9, p e0138747 (2015)

Signaling through the IL-1-receptor type 1 (IL-1R1), IL-1 is required for initiation and maintenance of diverse activities of the immune system. A second receptor, IL-1R2, blocks IL-1 signal transduction. We studied expression of IL-1beta, IL-1R1, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::83dde6cafe5197457cdc292570cf0a5b
https://pubmed.ncbi.nlm.nih.gov/26406983

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.

Autor: Schmid P; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom.; Oncology-Clinical, Barts Health National Health Service Trust, London, United Kingdom., Zaiss M; Praxis fuer Interdisziplinaere Onkologie, Freiburg, Germany., Harper-Wynne C; Kent Oncology Centre, Maidstone and Tunbridge Wells National Health Service Trust, Tunbridge Wells, United Kingdom., Ferreira M; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal., Dubey S; Oncology, Derriford Hospital, Plymouth Hospitals National Health System Trust, Plymouth, United Kingdom., Chan S; Oncology-Clinical, Nottingham University Hospitals National Health System Trust, Nottingham, United Kingdom., Makris A; Mount Vernon Cancer Centre, East & North Herts National Health System Trust, London, United Kingdom., Nemsadze G; Institute of Clinical Oncology, Tbilisi, Republic of Georgia., Brunt AM; Cancer Centre, University Hospitals of North Midlands National Health System Trust, Stoke-on-Trent, United Kingdom., Kuemmel S; Kliniken Essen-Mitte, Essen, Germany., Ruiz I; Hospital Universitario Sant Joan De Reus, Tarragona, Spain., Perelló A; Hospital Son Espases, Palma, Spain., Kendall A; Cancer Services, Great Western Hospitals National Health System Foundation Trust, Swindon, United Kingdom., Brown J; Academic Unit of Clinical Oncology, University of Sheffield, Sheffield, United Kingdom., Kristeleit H; Medical Oncology, Queen Elizabeth Hospital, Woolwich, Lewisham and Greenwich National Health System Trust, London, United Kingdom., Conibear J; Oncology-Clinical, Barts Health National Health Service Trust, London, United Kingdom., Saura C; Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Research Group, Vall d'Hebron University Hospital, Barcelona, Spain., Grenier J; Institut Sainte Catherine, Avignon, France., Máhr K; Zala County Hospital, Zalaegerszeg, Hungary., Schenker M; Sf Nectarie Oncology Center Societate cu Raspundere Limitata, Craiova, Dolj, Romania., Sohn J; Yonsei University Health System, Seoul, Republic of Korea., Lee KS; National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea., Shepherd CJ; Oncology Translational Medicine Unit, Innovative Medicines and Early Drug Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom., Oelmann E; Oncology Translational Medicine Unit, Innovative Medicines and Early Drug Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom., Sarker SJ; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom., Prendergast A; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom., Marosics P; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom., Moosa A; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom., Lawrence C; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom., Coetzee C; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom., Mousa K; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, United Kingdom., Cortés J; Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Research Group, Vall d'Hebron University Hospital, Barcelona, Spain.; Ramon y Cajal University Hospital, Madrid, Spain.; Baselga Oncology Institute, Institute of Oncology, QuironGroup, Madrid, Spain.

Publikováno v: JAMA oncology [JAMA Oncol] 2019 Nov 01; Vol. 5 (11), pp. 1556-1564.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.